(ii) Receptor tyrosine kinases (RTK): The activation of RTKs, such as EGFR, ERBB2, KIT, and PDGFR, by mutation or translocation directly leads to tumor growth and is a clear therapeutic target; these mutations were detected in 216 of 1003 cases or around 20% of the cases. This evidence concerns the gene ERBB2 and neoplasm.